Dialysis and Replacement Solutions for Pediatric CRRT

1
Dialysis and Replacement Solutions for Pediatric
CRRT

• Jordan M. Symons, MD
• University of Washington School of Medicine
• Childrens Hospital Regional Medical Center
• Seattle, WA
• jordan.symons_at_seattlechildrens.org

2
CRRT SolutionsOutline of the Talk

• Purpose of solutions in CRRT
• Goals for a CRRT solution
• Description of solutions currently available for
  CRRT
• Considerations in choosing a solution for CRRT

3
First CAVH Circuit
Kramer, P, et al. Arteriovenous haemofiltration
A new and simple method for treatment of
over-hydrated patients resistant to diuretics.
Klin Wochenschr 551121-2, 1977.
4
CAVH Good for Fluid Balance,Not So Good for
Metabolic Balance

• CAVH removes all molecules slowly
• Good for BP stability (slow UF)
• Not so good for metabolic control
• Need method to increase molecular clearance
  without increasing UF rate

5

• Diffusion
• Small molecules diffuse easily
• Larger molecules diffuse slowly
• Dialysate required
• Concentration gradient
• Faster dialysate flow increases mass transfer

6

• Convection
• Small/large molecules move equally
• Limit is cut-off size of membrane
• Higher UF rate yields higher convection but risk
  of hypotension
• May need to Replace excess UF volume

Neg Press
H2O
H2O
H2O
H2O
7
Solutions in CRRT Address Molecular Control Issues

• Improved mass transfer using diffusion,
  high-grade convection, or combination
• CVVH a pure convection modality
• CVVHD a diffusion modality
• CVVHDF combined convection/diffusion
• Permits correction of metabolic abnormalities
• Provides complete renal replacement

8
Characteristics of the Ideal CRRT Solution

• Physiological
• Reliable
• Inexpensive
• Easy to prepare
• Simple to store
• Quick to the bedside
• Widely available
• Fully compatible

9
Options for CRRT Solutions

• Peritoneal dialysate
• Pre-made IV solutions
• Saline, Lactated Ringers
• Multi-bag systems
• Custom-made solutions
• Local pharmacy outsource
• Commercially available CRRT solutions

NO
MAYBE
UNNECESSARY
RARELY
10
Commercial Solutions for CRRT Several Companies,
Multiple Options

• Previously limited options
• No bicarbonate-based solutions
• US regulations re drug vs. device
• Currently multiple manufacturers each offering a
  variety of formulations
• Bicarbonate as primary or only base
• The Choice may depend on local policy, vendors,
  economic pressures

11
Normocarb (DSI)

• Bicarbonate buffered
• Concentrate must be compounded
• Final volume 3.24 liters (240ml concentrate added
  to 3 L bag)

12
Chemical Content of Normocarb
13
Normocarb HF (DSI)

• Bicarbonate buffered
• Concentrate must be compounded
• Final volume 3.24 liters (240ml concentrate added
  to 3 L bag)
• 2 ionic formulations
• Normocarb HF 25
• Normocarb HF 35

14
Chemical Content of Normocarb HF
15
PrismaSate (Gambro)

• Bicarbonate buffered
• Small amount of lactate
• 5 liter bag
• 2 compartments to prevent precipitation
• Six ionic formulations

16
Chemical Content of PrismaSate
17
PrismaSol (Gambro)

• Bicarbonate buffered
• Small amount of lactate
• 5 liter bag
• 2 compartments to prevent precipitation
• Seven ionic formulations

18
Chemical Content of PrismaSol
19
Accusol (Baxter)

• Bicarbonate buffered
• No lactate
• 2.5 liter bag
• 2 compartments to prevent precipitation
• Five ionic formulations

20
Chemical Content of Accusol
21
Duosol (B.Braun)

• Bicarbonate buffered
• No lactate
• 5 liter bag
• 2 compartments to prevent precipitation
• Three ionic formulations

22
Chemical Content of Duosol
23
NxStage PureFlow (NxStage)

• Part of NxStage System One for acute care
• 5 liter bags
• Choice of buffers
• Lactate 3 formulations single-chamber bag
• Bicarbonate 5 formulations dual-chamber bag

24
Chemical Content of NxStage PureFlow (1)
25
Chemical Content of NxStage PureFlow (2)
26
Choosing a Solution Issues to Consider

• Cost
• Anticoagulation
• Patient safety
• CRRT modality
• Diffusion (CVVHD)
• Convection (CVVH)
• Both (CVVHDF)

27
Anticoagulation and Solutions
May need to consider Ca content if using
citrate for anticoagulation
28
Evaluation of Errors in Preparation of CRRT
Solutions

• Survey of 3 Pediatric Listserves
• Pediatric Critical Care, Nephrology, CRRT
• 16/31 programs reported solution compounding
  errors
• Consequences of improper solutions
• 2 deaths
• 1 non lethal cardiac arrest
• 6 seizures (hypo/hypernatremia)
• 7 without complications

Barletta et al, Pediatr Nephrol. 21(6)842-5,
2006 Jun
29
FDA Approval Status of CRRT Solutions
30
Putting it All Together One Approach

• CRRT with citrate regional anticoag

• DIALYSATE commercial bicarb-based solution

• REPLACEMENT normal saline

• Adjust blend, change saline if indicated

31
On-Line Dialysate with SLED An Alternative to
Solutions in CRRT

• Extended sessions using standard dialysis
  equipment
• Dialysate made on-line from concentrates
• Simple, convenient, MUCH cheaper
• Dialysate is not sterile

32
Citrasate(Advanced Renal Technologies)

• A concentrate for dialysis
• Liquid or bulk powder
• Citrate used as acidifying agent
• Local anticoagulation greatly reduces need for
  heparin

33
CRRT Solutions Summary

• Solutions needed to maximize clearance
• Bicarbonate has superseded lactate
• Industry-made solutions are available including
  some approved for replacement
• Pre-mixed, sterile solutions for CRRT are simple,
  safe, may be costly
• On-line dialysate for SLED is clean (not
  sterile), simple, cheap
• The best solution may still be pending

34
Thanks!